Evidence map›Paper›PMID 27184366›Full record

ArticleBMC infectious diseases2016

The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?

Steven T Pullan, Jon C Allnutt, Rebecca Devine, Kim A Hatch, Rose E Jeeves, Charlotte L Hendon-Dunn, Philip D Marsh, Joanna Bacon

Abstract read
In one paragraph

Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. MakingCell insight · 2026
    Review
  2. Article
  3. Article
  4. Enhancing diagnostic efficiency of pyrazinamide resistance inCurrent research in microbial sciences · 2025
    Article
  5. Metabolites fromACS omega · 2023
    Article
  6. Variability ofAntibiotics (Basel, Switzerland) · 2022
    Review
  7. Review
  8. Are all antibiotic persisters created equal?Frontiers in cellular and infection microbiology · 2022
    Review
  9. Article
  10. Article
  11. Re-growth ofAntimicrobial agents and chemotherapy · 2019
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Steven T PullanPublic Health England, National Infection Service, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Jon C AllnuttPublic Health England, National Infection Service, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Rebecca DevineSchool of Biological Sciences, University of East Anglia, Norwich Research Park, NR4 7TJ, UK.
Kim A HatchPublic Health England, National Infection Service, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Rose E JeevesPublic Health England, National Infection Service, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Charlotte L Hendon-DunnPublic Health England, National Infection Service, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Philip D MarshPublic Health England, National Infection Service, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
Joanna BaconPublic Health England, National Infection Service, Porton Down, Salisbury, Wiltshire, SP4 0JG, UK. Joanna.bacon@phe.gov.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPyrazinamide (PZA) plays an essential part in the shortened six-month tuberculosis (TB) treatment course due to its activity against slow-growing and non-replicating organisms. We tested whether PZA preferentially targets slow growing cells of Mycobacterium tuberculosis that could be representative of bacteria that remain after the initial kill with isoniazid (INH), by observing the response of either slow growing or fast growing bacilli to differing concentrations of PZA.

methodsM. tuberculosis H37Rv was grown in continuous culture at either a constant fast growth rate (Mean Generation Time (MGT) of 23.1 h) or slow growth rate (69.3 h MGT) at a controlled dissolved oxygen tension of 10 % and a controlled acidity at pH 6.3 ± 0.1. Cultures were exposed to step-wise increases in the concentration of PZA (25 to 500 μgml(-1)) every two MGTs, and bacterial survival was measured. PZA-induced global gene expression was explored for each increase in PZA-concentration, using DNA microarray.

resultsAt a constant pH 6.3, actively dividing mycobacteria were susceptible to PZA, with similar responses to increasing concentrations of PZA at both growth rates. Three distinct phases of drug response could be distingished for both slow growing (69.3 h MGT) and fast growing (23.1 h MGT) bacilli. A bacteriostatic phase at a low concentration of PZA was followed by a recovery period in which the culture adapted to the presence of PZA and bacteria were actively dividing in steady-state. In contrast, there was a rapid loss of viability at bactericidal concentrations. There was a notable delay in the onset of the recovery period in quickly dividing cells compared with those dividing more slowly. Fast growers and slow growers adapted to PZA-exposure via very similar mechanisms; through reduced gene expression of tRNA, 50S, and 30S ribosomal proteins.

conclusionsPZA had an equivalent level of activity against fast growing and slow growing M. tuberculosis. At both growth rates drug-tolerance to sub-lethal concentrations may have been due to reduced expression of tRNA, 50S, and 30S ribosomal proteins. The findings from this study show that PZA has utility against more than one phenotypic sub-population of bacilli and could be re-assessed for its early bactericidal activity, in combination with other drugs, during TB treatment.

Indexed as

Antitubercular AgentsGene Expression ProfilingGene Expression Regulation, BacterialIsoniazidMycobacterium tuberculosisPyrazinamideRibosomal ProteinsRNA, TransferAntitubercular AgentsIsoniazidPyrazinamideRibosomal ProteinsRNA, TransferChemostatsGene expressionGrowth rateMycobacterium tuberculosisPyrazinamidetrans-translation

Identifiers

PMID27184366
PMCPMC4869200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.